P A I D A D V E R T I S E M E N T
 |
| |
| |
Dear MDM User: We’re writing to let you know that there is now a research study enrolling patients and you or your loved one may be eligible. MINDSET is a Phase III clinical research program evaluating an investigational medication called RVT-101 for mild–to-moderate Alzheimer’s disease. The MINDSET program is led by Dr. Lawrence Friedhoff, who previously led the development and regulatory approval of Aricept® (donepezil), the most widely used treatment for Alzheimer’s disease.
An earlier study of RVT-101 in combination with donepezil suggested statistically significant benefits in cognition and function in subjects, as compared to donepezil alone. This larger study is designed to confirm the results of the earlier study in people with mild-to-moderate Alzheimer’s.
To find out more, please visit AlzheimersGlobalStudy.com, and take our questionnaire to see if you pre-qualify for study participation. Thank you for your interest, Danna Walls
Nurse Navigator for Clinical Research
MINDSET Study Team |
| |
HIPPA Disclaimer: The Health Insurance Portability and Accountability Act (HIPAA) of 1996 standardized the electronic exchange of sensitive patient data to protect patients from unauthorized disclosure of their medical data. In compliance with these standards, the materials in this e-mail are private and may contain Protected Health Information. If you are not the intended recipient be advised that any unauthorized use, disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this email in error, or you have any question about the specific content of this message, please notify us at admin@studymanager.org and a member of our team will be happy to call and follow up with you. Please leave your phone number and the best time for contact. |
|
.jpg)
.jpg)
